Cancer Biology

1218 Treatment with a specific inhibitor of the N6-methyladenosine methyltransferase METTL3 leads to reduced growth of cancer cells, indicating the potential of approaches targeting RNA-modifying enzymes for anticancer therapy.

1217 Positron emission tomography measurements of nutrient uptake in cells of the tumour microenvironment reveal cell-intrinsic partitioning in which glucose uptake is higher in myeloid cells, whereas glutamine is preferentially acquired by cancer cells.

1216 Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis.

1215 Platinum(II) N-heterocyclic carbene complexes arrest metastatic tumor growth.

1214 Combining IL-15 superagonist and anti-GITR agonist therapy enhances antitumor effects of radiation therapy in a mouse model of mesothelioma.

1213 A phase 1 clinical trial provides evidence that a vaccine against mutant IDH1 is safe and produces a T helper immune response in patients with glioma.

1212 Epigenetic reprogramming of tumor cell–intrinsic STING function sculpts antigenicity and T cell recognition of melanoma.

1211 Lysosomal retargeting of Myoferlin mitigates membrane stress to enable pancreatic cancer growth.

1210 Mitochondrial copper depletion suppresses triple-negative breast cancer in mice.

1209 Myeloid cell–derived HOCl is a paracrine effector that trans-inhibits IKK/NF-κB in melanoma cells and limits early tumor progression.

1208 Breast tumours maintain a reservoir of subclonal diversity during expansion.

1207 Acute myeloid leukemia cells are dependent on the DNA repair function of valosin-containing protein, opening up an avenue for disease treatment.

1206 Identification of bacteria-derived HLA-bound peptides in melanoma.

1205 A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.

1204 A role for keratin 17 during DNA damage response and tumor initiation.

1203 T cells engineered with synthetic receptors that integrate components of T cell and B cell receptors show efficacy against solid tumors in mice.

1202 TCR β chain–directed bispecific antibodies for the treatment of T cell cancers.

1201 RNA interference–based spherical nucleic acid nanoconjugates are a potentially safe and brain-penetrant approach for glioblastoma treatment.

1200 Identification of a metabolic checkpoint involving lipid signalling that is specific to regulatory T cells (Treg cells) in the tumour microenvironment raises the possibility of targeting this checkpoint for treatment of cancer.

1199 In mouse models of pancreatic cancer, a cooperative interaction between tissue damage and Kras gene mutation rapidly induces cancer-associated chromatin states in pre-malignant tissue, leading to gene dysregulation and neoplastic transformation.

Free Images for Presentation: sunipix SUNIPIX